BACKGROUND Recent studies showed that lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular disease
, induces macrophage apoptosis (6) , and is integrally involved in initiating and potentially destabilizing atherosclerotic lesions (7) . This finding is clinically substantiated by showing that the risk of Lp(a) is primarily driven by its content of oxidized phospholipids present in patients with high Lp(a) levels and small apo(a) isoforms (5, 8, 9) .
The evidence for a causal role of Lp(a) in CVD is based on strong data from large epidemiological databases (10) , mendelian randomization studies starting in the 1990s (11) , and genome-wide association studies linking genetically determined Lp(a) levels to CVD events, such as by KIV-2 repeats or various SNPs influencing Lp(a) levels (12, 13) . Epidemiological studies suggest a log-linear relationship between circulating levels of Lp(a) and the risk of CVD that is independent of other lipid measures and conventional risk factors (14) (15) (16) (17) (18) . Mendelian randomization studies demonstrate a causal, multivariable-adjusted, linear association between genetically determined Lp(a) levels and CVD risk (14, 19, 20) . Finally, genome-wide association studies show that the LPA variants are strongly associated with reduced copy numbers of KIV-2 repeats, increased Lp(a) levels, and higher risk of coronary artery disease (CAD) (12, 20) .
These epidemiological and genetic studies suggest that measuring Lp(a) would enhance risk prediction and that Lp(a) should be a target of therapy (21) . In that regard, it would be important to document that measuring Lp(a) levels allows clinicians to reclassify patients correctly into categories of lower or higher predicted risk using accepted risk algorithms. Therefore, the goal of this study was to assess whether Lp(a) allows reclassification of CVD risk by using a variety of methods. Because Lp(a) levels are genetically mediated, we assessed reclassification based on the Reynolds Risk Score (RRS), which additionally encompasses a family history of CVD and highsensitivity C-reactive protein (hs-CRP).
METHODS
The Bruneck Study is a prospective population-based survey of the epidemiology and pathogenesis of atherosclerosis enrolling a sex-and age-stratified random sample of all inhabitants of Bruneck, Italy (125 women and 125 men, all in their fifth to eighth decade of age) (22) . The current investigation focuses on blood samples from the 1995 examination and the follow-up period for clinical events between 1995 and 2010. In 1995, the study population consisted of 826 subjects, and plasma samples for assessment of Lp(a) were available in all participants. The ethics committees of Verona and Bolzano approved the study protocol, and all study subjects gave their written informed consent before entering the study.
All risk factors were assessed by validated standard procedures.
STUDY METHODOLOGY AND LABORATORY METHODS.
Study methodology and laboratory methods for factors listed in Table 1 were previously described in detail (8, (22) (23) (24) . Determination of apolipoprotein(a) isoforms and measurement of allele-specific Lp(a) levels are available in the Online Appendix. Second, we evaluated whether Lp(a) measurement helps correctly classify participants into categories of predicted CVD risk. Using the risk categories <7.5%, 7.5% to <15%, 15% to <30%, and $30%, the categorical net reclassification improvement (NRI) (25) was calculated for participants who experienced a CVD event within 15 years of follow-up (n ¼ 148 in the study cohort) and for those who remained free of CVD throughout the entire survey period (n ¼ 502).
The authors also computed the prospective variant of the categorical NRI, which additionally includes Values are mean AE SD or n (%). *High Lp(a) corresponds to the top fifth (i.e., >45 mg/dl). †Analysis was based on 822 participants with information on apo(a) isoform available with 147 incident CVD events. ‡To convert values for cholesterol to mmol/l, multiply by 0.02586. §Median and interquartile range is presented for high-sensitivity C-reactive protein. 
7). In a comparison of participants in the top
fifth of Lp(a) levels to the remainder, the age-and sex-adjusted HR for CVD was 2.34 (1.67 to 3.29)
( Table 3 CI ¼ confidence interval; other abbreviations as in Table 1 .
Willeit et al. were correctly reclassified to a higher-risk category and 17 were reclassified to a lower-risk category.
Third, we calculated the NRI and IDI for CVD ( . other abbreviations as in Figure 1 . NRI ¼ net reclassification improvement; other abbreviations as in Table 1 . combination of Lp(a) levels and LPA genotypes did not enhance NRI or IDI for coronary heart disease and slightly enhanced it for MI. Although differences exist among the current study and the 2 foregoing studies, they are all remarkably consistent in enhancing risk prediction by adding Lp(a) to conventional risk factors.
In the current study, neither apo(a) isoforms nor allele-specific Lp(a) levels (32) added to the predictive ability of FRS or RRS, nor to Lp(a), unlike earlier studies (11, 33) . In a prior study from Bruneck that In view of accumulating data from epidemiological, genetic association, and mendelian randomization studies, Lp(a) has become a target of therapy (21) . The antisense inhibitor mipomersen, approved to lower LDL-C levels in patients with homozygous familial hypercholesterolemia, lowers Lp(a) levels 21% to 39% (36) . Cholesterol ester transferase protein (CETP) inhibitors and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies currently in trials also lower Lp(a) up to 40% (21, 37) .
Finally, specific antisense inhibitors to apo(a) have been tested in both animal models (38) and in phase I Kiechl@i-med.ac.at.
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